1. Home
  2. SSEA vs LUNG Comparison

SSEA vs LUNG Comparison

Compare SSEA & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SSEA
  • LUNG
  • Stock Information
  • Founded
  • SSEA 2024
  • LUNG 1995
  • Country
  • SSEA United States
  • LUNG United States
  • Employees
  • SSEA N/A
  • LUNG N/A
  • Industry
  • SSEA
  • LUNG Industrial Specialties
  • Sector
  • SSEA
  • LUNG Health Care
  • Exchange
  • SSEA Nasdaq
  • LUNG Nasdaq
  • Market Cap
  • SSEA 76.3M
  • LUNG 63.6M
  • IPO Year
  • SSEA 2025
  • LUNG 2020
  • Fundamental
  • Price
  • SSEA $9.99
  • LUNG $1.41
  • Analyst Decision
  • SSEA
  • LUNG Buy
  • Analyst Count
  • SSEA 0
  • LUNG 7
  • Target Price
  • SSEA N/A
  • LUNG $6.81
  • AVG Volume (30 Days)
  • SSEA 45.7K
  • LUNG 7.0M
  • Earning Date
  • SSEA 01-01-0001
  • LUNG 11-12-2025
  • Dividend Yield
  • SSEA N/A
  • LUNG N/A
  • EPS Growth
  • SSEA N/A
  • LUNG N/A
  • EPS
  • SSEA N/A
  • LUNG N/A
  • Revenue
  • SSEA N/A
  • LUNG $91,664,000.00
  • Revenue This Year
  • SSEA N/A
  • LUNG $10.41
  • Revenue Next Year
  • SSEA N/A
  • LUNG $10.98
  • P/E Ratio
  • SSEA N/A
  • LUNG N/A
  • Revenue Growth
  • SSEA N/A
  • LUNG 15.59
  • 52 Week Low
  • SSEA $9.93
  • LUNG $1.35
  • 52 Week High
  • SSEA $10.00
  • LUNG $9.37
  • Technical
  • Relative Strength Index (RSI)
  • SSEA N/A
  • LUNG 39.77
  • Support Level
  • SSEA N/A
  • LUNG $1.65
  • Resistance Level
  • SSEA N/A
  • LUNG $2.11
  • Average True Range (ATR)
  • SSEA 0.00
  • LUNG 0.17
  • MACD
  • SSEA 0.00
  • LUNG -0.05
  • Stochastic Oscillator
  • SSEA 0.00
  • LUNG 7.24

About SSEA Starry Sea Acquisition Corp Ordinary Shares

Starry Sea Acquisition Corp is a newly organized blank check company.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: